Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects

A pharmacokinetics (PK)/pharmacodynamics (PD) study (EudraCT number 2015‐002966‐21) was conducted to investigate the biosimilarity of Pelmeg(®) (pegfilgrastim), a biosimilar to EU‐authorized Neulasta(®), which is used in the clinic for prevention of chemotherapy‐induced neutropenia. The single‐dose,...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Karsten, Lehnick, Dirk, Wessels, Hendrik, Höfler, Josef, Gastl, Barbara, Jankowsky, Ruediger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691757/
https://www.ncbi.nlm.nih.gov/pubmed/31417680
http://dx.doi.org/10.1002/prp2.503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691757/
https://www.ncbi.nlm.nih.gov/pubmed/31417680
http://dx.doi.org/10.1002/prp2.503

Ejemplares similares